Scientific Advisory Board
Andrea Amalfitano, D.O. PhD, Chairman of Scientific Advisory Board
Dr. Andrea Amalfitano is Chairman of Etubics' Scientific Advisory Board. A pioneering gene therapist, Dr. Amalfitano received both his PhD and medical degree from Michigan State University and performed his residency at the Mayo Clinic. While at the University of Michigan he was instrumental in creating Etubics' adenovirus constructions, as well as the packaging cell lines critical for the production of the adenoviral vaccines. Dr. Amalfitano continued his gene therapy research as a professor at Duke University Medical Center. He is presently at Michigan State University where he was appointed the Osteopathic Heritage Foundation Endowed Chairperson. Dr. Amalfitano continues his work using adenoviral vectors for vaccine development and gene therapy.
John H. Lee, MD
Dr. Lee is a certified surgeon and an Associate Professor and Research Director in the department of Otolaryngology at Sanford Health Systems, Sioux Falls, SD. He has been a head and neck surgeon for over 10 years and has focused his pre-clinical research on HPV 16 induction of and detection of cancers. He is Director of HPV Research Labs at Sanford Cancer Research Center. He has published on HPV targets for both anchorage and immunogenicity. Dr Lee received his undergraduate education at Stanford University and his Medical Degree at University of Minnesota. He then received surgical training at the University of Iowa's ENT residency program, where he published over 20 articles and book chapters.
H. Kim Lyerly, MD
Dr. Lyerly is the Director of Duke Comprehensive Cancer Center, Durham, NC, and directs the programs for the Center. He is a pioneer in the development and testing of immunologic therapies– therapies that employ the body’s own immune system to fight cancer. Dr. Lyerly is nationally and internationally recognized for developing and leading novel clinical trials that evaluated the use of dendritic cells targeting HER2/neu, CEA and RNA (ribonucleic acid) as a therapeutic vaccine to fight primary cancers as well as protect patients against recurrences. He has brought immunotherapy from the bench to the bedside and now leads the team that is performing the first in man clinical trial using the Company's Ad5 [E1-, E2b-]-CEA platform to treat colon and other cancer patients. Dr. Lyerly has chaired the American Society of Clinical Oncology's Grant Selection committee and is a professor at Duke University School of Medicine. He currently sits on the editorial boards of several peer-reviewed journals, including Cancer Investigation, Clinical Cancer Research, and Cancer Gene Therapy. He has published nearly 200 papers and book chapters, and has edited or co-edited 7 books.
A. Dusty Miller, PhD
Dr. A. Dusty Miller is a member of the Company's Scientific Board of Advisors and a Consultant to the Company. He is an early pioneer in gene therapy research. He is a member of Fred Hutchinson Cancer Reach Center's Divisions of Human Biology and Basic Sciences and an affiliate professor of pathology at the University of Washington, both in Seattle, WA. Dr. Miller has focused on the development of viral vectors derived from retroviruses and adeno-associated viruses and has demonstrated gene transfer and expression in many somatic cell types in culture and animals. Other ongoing development work focuses on the basic biology and properties of adeno-associated virus vectors and their potential for use in gene therapy and on retrovirus biology, including the nature of the receptors used for entry or retroviruses into cells and the evolution of the retrovirus envelope proteins that interact with these receptors. More recently his work has included studies of lung cancer caused by sheep retroviruses. Dr. Miller advises Etubics in the area of adeno-vector immunization against infectious diseases and immunotherapy of cancers.
James J. Mulé, PhD
Dr. James J. Mulé is a member of the Company’s Scientific Board of Advisors and a Consultant to the Company. He is an internationally known senior cancer immunologist and gene therapist. Currently, he is the Executive Vice President, Applied Research, of the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL. and holds the U.S. Senator Connie Mack Distinguished Chair in Melanoma Research and Treatment. Previously, Dr. Mulé was a professor in the Departments of Surgery and Internal Medicine at the University of Michigan. Dr. Mulé is a consultant to the National Cancer Institute, the National Institutes of Health, and is on several governmental and publication advisory boards. He has spoken around the world on cancer immunology, cancer vaccines and gene therapy. He has published over 130 scientific papers in the field of tumor immunology and immunotherapy.